Abstract
Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Current Pharmaceutical Design
Title: Treatment of Patients with Schizophrenia and Substance Abuse Disorders
Volume: 10 Issue: 18
Author(s): John Tsuang and Timothy W. Fong
Affiliation:
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Abstract: Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Export Options
About this article
Cite this article as:
Tsuang John and Fong W. Timothy, Treatment of Patients with Schizophrenia and Substance Abuse Disorders, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384114
DOI https://dx.doi.org/10.2174/1381612043384114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Recent Progress in Drug Discovery for Parkinson's Disease)
Current Topics in Medicinal Chemistry Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry Evaluation of the Antipsychotic Effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one Derivatives in Experimental Model of Psychosis in Mice
Current Topics in Medicinal Chemistry Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Current Neuropharmacology Development and Applications of Non-HIV-Based Lentiviral Vectors in Neurological Disorders
Current Gene Therapy Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Current Topics in Medicinal Chemistry AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors
Current Pharmaceutical Design Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research